Last updated on December 2018

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy


Brief description of study

Primary Objective:

To demonstrate the superiority of sotagliflozin dose 1 versus placebo on hemoglobin A1c (HbA1c) reduction in patients with type 2 diabetes (T2D) who have inadequate glycemic control on diet and exercise.

Secondary Objectives:

  • To compare sotagliflozin dose 1 versus placebo based on:
  • Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal;
  • Change from baseline in fasting plasma glucose (FPG);
  • Change from baseline in systolic blood pressure (SBP) for patients with baseline SBP 130 mmHg;
  • Change from baseline in SBP for all patients;
  • Change from baseline in body weight;
  • Proportion of patients with HbA1c <6.5%, <7.0%.
  • To compare sotagliflozin dose 2 versus placebo based on:
  • Change from baseline in HbA1c
  • Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal;
  • Change from baseline in body weight;
  • Change from baseline in SBP for all patients.
  • To evaluate the safety of sotagliflozin doses 1 and 2 versus placebo.

Detailed Study Description

Up to 34 weeks, including a Screening Period consisting of a Screening Phase of up to 2 weeks and a 2-week single-blind placebo Run-in Phase, a 26-week double-blind Treatment Period, and a 4-week post-treatment Follow-up visit to collect safety information.

Clinical Study Identifier: NCT02926937

Contact Investigators or Research Sites near you

Start Over

Investigational Site Number 8401024

Bradenton, FL United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.